肝癌患者血清microRNA-363 水平在诊断 和病情评估中的价值

Serum miR-363 level in patients with liver cancer and its value in diagnosis and disease assessment

摘要:

目的 探讨肝癌患者血清microRNA-363（miR-363）水平与肝癌临床病理特征的关系及其在肝 癌诊断中的价值。方法 选取2016 年1 月—2018 年12 月台州医院肝胆胰外科收治的肝细胞肝癌患者86 例作 为肝癌组，选取同期该院健康体检者86 例作为对照组。RT-PCR 测定血清miR-363 水平。结果 肝癌组血 清miR-363 相对表达量低于对照组（P <0.05），AFP 水平高于对照组（P <0.05）。不同TNM 分期、有无转移 患者血清miR-363 相对表达量比较，差异有统计学意义（P <0.05）。肝癌患者血清miR-363 与AFP 呈负相关 （r =-0.502，P <0.05）。miR-363、AFP 及miR-363+AFP 诊断肝癌的ROC 曲线下面积分别为0.742（95% CI ： 0.740，0.747）、0.884（95% CI ：0.881，0.887）和0.938（95% CI ：0.935，0.941），敏感性分别为0.907（95% CI ： 0.876，0.932）、0.872（95% CI ：0.843，0.900）和0.826（95% CI ：0.796，0.855），特异性分别为0.663（95% CI ：0.643，0.673）、0.802（95% CI ：0.782，0.824）和0.930（95% CI ：0.903，0.962）。结论 肝癌患者血清miR-363 水平降低，血清miR-363 与肝癌TNM 分期、转移关系密切，在协助肝癌诊断中具有一定指导价值。

Abstract:

Objective To investigate the serum miR-363 level of liver cancer and its relationship with clinicopathological features and its value in the diagnosis of liver cancer. Methods From January 2016 to December 2018 in Taizhou Hospital, patients with primary liver cancer were selected as the liver cancer group, and 86 healthy subjects were selected as the control group. The serum miR-363 level was determined by reverse transcriptionpolymerase chain reaction (RT-PCR). Results The serum miR-363 level in the liver cancer group was lower than that in the control group (P < 0.05), and the AFP level was higher than that in the control group (P < 0.05). There was significant difference in the relative expression of mir-363 in different TNM stages and with or without metastasis (P < 0.05). There were significant differences in the levels of serum miR-363 with different TNM staging and metastasis (P < 0.05).The serum miR-363 level was negatively correlated with AFP levels in patients with liver cancer (r = -0.502, P < 0.05). The areas under the ROC curve of miR-363, AFP, miR-363+AFP for diagnosis of liver cancer were 0.742 (95% CI: 0.740, 0.747), 0.884 (95% CI: 0.881, 0.887) and 0.938 (95% CI: 0.935, 0.941), respectively; the sensitivities were 90.70% (95% CI: 87.56, 93.21), 87.21% (95% CI: 84.32, 90.03), 82.56% (95% CI: 0.796, 0.855); the specificities were 66.28% (95% CI: 0.643, 0.673), 80.23% (95% CI: 0.782, 0.824) and 93.02% (95% CI :0.903, 0.962). Conclusion Serum miR-363 level is decreased in patients with liver cancer, and serum miR-363 has a certain guiding value in the assessment of severity and diagnosis of liver cancer.